OncoMed Pharmaceuticals Inc. (OMED) Sank To A New Low After Study Failed

OncoMed Pharmaceuticals Inc. (OMED) announced Monday morning that its Phase 2 trial of demcizumab in combination with Abraxane plus gemcitabine, in previously untreated patients with metastatic pancreatic cancer, did not meet the primary endpoint of progression-free survival.

from RTT - Before the Bell http://ift.tt/2nYDpE5
via IFTTT